Prodotti competitors / Area Oncology
FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer
On August 2, 2023, the Food and Drug Administration (FDA) approved trifluridine and tipiracil (Lonsurf Taiho Oncology, Inc.) with bevacizumab, for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
FDA had previously approved single-agent Lonsurf for this indication in September 2015.
Grazie per il tuo feedback!